These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33743528)

  • 1. Teprotumumab: The First Approved Biologic for Thyroid Eye Disease.
    Hwang CJ; Eftekhari K
    Int Ophthalmol Clin; 2021 Apr; 61(2):53-61. PubMed ID: 33743528
    [No Abstract]   [Full Text] [Related]  

  • 2. Teprotumumab: First Approval.
    Markham A
    Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teprotumumab for the treatment of thyroid eye disease.
    Ju Y; Yang J
    Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.
    Ali F; Chorsiya A; Anjum V; Ali A
    Int Ophthalmol; 2021 Apr; 41(4):1549-1561. PubMed ID: 33481154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
    Smith TJ
    Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.
    Chern A; Dagi Glass LR; Gudis DA
    Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teprotumumab for Asymmetric Thyroid Eye Disease.
    Ugradar S; Wang Y; Douglas R
    Ophthalmology; 2021 Oct; 128(10):1416. PubMed ID: 34556309
    [No Abstract]   [Full Text] [Related]  

  • 9. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
    Kossler AL; Douglas R; Dosiou C
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teprotumumab for Inactive Thyroid Eye Disease? The Jury Is Still Out.
    Dosiou C
    J Clin Endocrinol Metab; 2024 Aug; 109(9):e1802-e1803. PubMed ID: 38279938
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of teprotumumab in thyroid eye disease.
    Greenhill C
    Nat Rev Endocrinol; 2021 Jul; 17(7):383. PubMed ID: 33953374
    [No Abstract]   [Full Text] [Related]  

  • 12. Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab.
    Hwang CJ; Nichols EE; Chon BH; Perry JD
    Eur J Ophthalmol; 2022 May; 32(3):NP46-NP49. PubMed ID: 33525898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
    Slentz DH; Nelson CC; Smith TJ
    Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teprotumumab (Tepezza) for thyroid eye disease.
    Med Lett Drugs Ther; 2021 May; 63(1625):87-88. PubMed ID: 34101720
    [No Abstract]   [Full Text] [Related]  

  • 15. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teprotumumab for Thyroid Eye Disease.
    Hwang CJ; Eftekhari K
    Int Ophthalmol Clin; 2020; 60(2):47-55. PubMed ID: 32205652
    [No Abstract]   [Full Text] [Related]  

  • 17. Acquired Epiblepharon Alleviated With Teprotumumab Treatment in Active Thyroid Eye Disease Patient.
    Chen KW; Phelps PO
    Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):e195-e196. PubMed ID: 34269764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?
    Bartalena L; Marinò M; Marcocci C; Tanda ML
    J Endocrinol Invest; 2022 Jul; 45(7):1455-1457. PubMed ID: 35403994
    [No Abstract]   [Full Text] [Related]  

  • 19. Teprotumumab for Optic Neuropathy in Thyroid Eye Disease.
    Slentz DH; Smith TJ; Kim DS; Joseph SS
    JAMA Ophthalmol; 2021 Feb; 139(2):244-247. PubMed ID: 33270090
    [No Abstract]   [Full Text] [Related]  

  • 20. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.